KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Inventory (2016 - 2025)

Historic Inventory for Travere Therapeutics (TVTX) over the last 12 years, with Q3 2025 value amounting to $5.5 million.

  • Travere Therapeutics' Inventory fell 1271.24% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 1271.24%. This contributed to the annual value of $6.2 million for FY2024, which is 3411.26% down from last year.
  • Per Travere Therapeutics' latest filing, its Inventory stood at $5.5 million for Q3 2025, which was down 1271.24% from $4.1 million recorded in Q2 2025.
  • Travere Therapeutics' 5-year Inventory high stood at $20.8 million for Q3 2023, and its period low was $3.9 million during Q1 2025.
  • Moreover, its 5-year median value for Inventory was $6.6 million (2021), whereas its average is $7.7 million.
  • Its Inventory has fluctuated over the past 5 years, first surged by 18467.86% in 2023, then crashed by 6940.26% in 2024.
  • Over the past 5 years, Travere Therapeutics' Inventory (Quarter) stood at $7.3 million in 2021, then plummeted by 38.15% to $4.5 million in 2022, then skyrocketed by 108.05% to $9.4 million in 2023, then tumbled by 34.11% to $6.2 million in 2024, then dropped by 10.52% to $5.5 million in 2025.
  • Its last three reported values are $5.5 million in Q3 2025, $4.1 million for Q2 2025, and $3.9 million during Q1 2025.